A cabazitaxel liposome for increased solubility, enhanced antitumor effect and reduced systemic toxicity
Authors:
Open Access
- 1 November 2019
- journal article
- research article
- Published by Elsevier in Asian Journal of Pharmaceutical Sciences
- Vol. 14 (6) , 658-667
Abstract
No abstract availableKeywords
Funding Information
- National Key R&D Program of China (No.2017YFE0102200)
- Natural Science Foundation of China (81373348 and 81573365)
- Basic Public Welfare Research Project of Zhejiang Province, China (LGF18H300004)
This publication has 21 references indexed in Scilit:
- Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant TumorsClinical Cancer Research, 2013
- The European Medicines Agency Review of Cabazitaxel (Jevtana®) for the Treatment of Hormone-Refractory Metastatic Prostate Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human UseThe Oncologist, 2012
- A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: A phase I/II studyEuropean Journal of Cancer, 2011
- Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancerDrug Design, Development and Therapy, 2011
- Nanoparticles: A personal experience for formulating poorly water soluble drugsJournal of Controlled Release, 2010
- Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid TumorsClinical Cancer Research, 2009
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Alternative drug formulations of docetaxel: a reviewAnti-Cancer Drugs, 2007
- Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactionsAnnals of Allergy, Asthma & Immunology, 2005
- Microtubules as a target for anticancer drugsNature Reviews Cancer, 2004